

MBL ELISA KITS

MBL Oligomer ELISA Kit (KIT 029)

MBL Mannan-binding ELISA Kit (KIT 030)

For human serum or plasma

MBL measurements are important if you are working with:

- Patients receiving
 - cancer chemotherapy
 - immunosuppressive treatment
- Children with recurrent infections
- Patients with autoimmune diseases



ANTIBODYSHOP

CE

SCIENTIFIC BACKGROUND

CLINICAL SIGNIFICANCE

There are many clinical conditions in which deficiency of normally oligomerized MBL is associated with increased susceptibility to infections or increased disease severity. The most important include:

- **Immunosuppression**
 - during cancer chemotherapy^{1,2}
 - after organ transplantation
- **Immature adaptive immune system**
 - in early childhood³
- **Autoimmune diseases (increased disease severity)**
 - systemic lupus erythematosus (SLE)⁴
 - rheumatoid arthritis⁵

Serum and plasma levels of normally oligomerized MBL range from 0-8000 ng/mL. Investigations have shown that up to 12% of the blood donors⁶ have low (<50 ng/mL) MBL plasma concentrations, as measured with the antibody in the Oligomer kit. These low values are associated with poor activation of complement via the lectin pathway.

MBL* – A KEY PLAYER IN COMPLEMENT ACTIVATION

MBL is an important factor in innate immunity.

On specific binding to microbial surface carbohydrates, MBL activates the complement system by means of its own lectin pathway, depending on the MBL-associated serine proteases (MASPs). This eventually leads to phagocytosis or lysis of pathogenic microorganisms, including bacteria, viruses, protozoa and fungi.

Only the normally oligomerized forms of MBL are functional and therefore capable of associating with the MASPs and binding efficiently to the microbial carbohydrates.

*MBL is also called mannan-binding lectin or protein




Figure 1.

Complement activation pathways with focus on the mannan-binding lectin activation pathway

MBL ELISA KITS FOR IN VITRO DIAGNOSTICS

CHOOSE THE RIGHT MBL KIT FOR YOUR APPLICATION

NEW

MBL Mannan-binding ELISA Kit (KIT 030) CE

- Especially suited when testing patients with autoimmune diseases - independent of interference from rheumatoid factors
- Measures only MBL capable of binding to mannan

MBL Oligomer ELISA Kit (KIT 029)^{7,8,9} CE

- Clinically accepted worldwide
- Measuring only the oligomerised form of MBL



KIT FEATURES

High reproducibility and easy to use

- Ready-to-use calibrators and working solutions
- Pre-coated ELISA strips
- All incubations performed at room temperature

Easy storage

- All components are stored at 4°C

Kit size

- 96 wells (12 eight-well strips), yielding 40 test results with double determinations

Versatility

- Measures MBL concentrations in both serum and plasma

Assay time


- Results in less than 4 hours

ASSAY PROCEDURE

MBL Oligomer ELISA Kit MBL Mannan-binding ELISA Kit



Plates are pre-coated and ready-to-use



Quantitative results are obtained by measuring the absorbance reading at 450 nm

Total assay time less than 4 hours

PRODUCTS

Code No.	Product description	Conjugation*
ELISA kits for in vitro diagnostics		
KIT 029	MBL Oligomer ELISA Kit, CE	-
KIT 030	MBL Mannan-binding ELISA Kit, CE	-
Monoclonal antibodies		
HYB 131-01	Mouse monoclonal anti-human MBL antibody	B, HRP, FITC
HYB 131-10	Mouse monoclonal anti-human MBL antibody	B
HYB 131-11	Mouse monoclonal anti-human MBL antibody	B
Control sera		
SER 101	MBL standard serum (1000 AU)	-
SER 102	MBL oligomer deficient serum, B/B genotype	-

*B: Biotin; HRP: Horse radish peroxidase; FITC: Fluorescein

REFERENCES

1. Peterslund NA, Koch C, Jensenius JC, Thiel S (2001) Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. *Lancet* 358:637-638.
2. Ytting H, Christensen IJ, Jensenius HC, Thiel S, Nielsen HJ (2005) Preoperative mannan-binding lectin pathway and prognosis in colorectal cancer. *Cancer Immunol Immunother* 54:265-272.
3. Koch A, Melbye M, Sørensen P, Homoe P, Madsen HO, Mølbak K, Hansen CH, Andersen LH, Hahn GW, Garred P (2001) Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. *JAMA* 285:1316-1321.
4. Garred P, Vos A, Madsen HO, Junker P (2001) Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. *Genes Immun* 2:442-450.
5. Saevarsdottir S, Vikingsdottir T, Vikingsson A, Manfredsdottir V, Geirsson AJ, Valdimarsson H (2001) Low mannose binding lectin predicts poor prognosis in patients with early rheumatoid arthritis. A prospective study. *J Rheumatol* 28:728-734.
6. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC (2000) Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. *J Immunol Methods* 241:33-42.
7. Fidler KJ, Wilson P, Davies JC, Turner MW, Peters MJ, Klein NJ (2004) Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin. *Intensive Care Med* 30:1438-1445.
8. Megia A, Gallart L, Fernández-Real JM, Vendrell J, Simón I, Gutierrez C, Richart C (2004) Mannose-Binding Lectin Gene Polymorphisms Are Associated with Gestational Diabetes Mellitus. *J Clin Endocrinol Metab* 89:5081-5087.
9. Heggelund L, Mollnes TE, Ueland T, Christophersen B, Aukrust P, Froland SS (2003) Mannose-binding lectin in HIV infection: relation to disease progression and highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 32:354-361.

For more information please contact **ANTIBODYSHOP** or your local distributor



ANTIBODYSHOP

ANTIBODYSHOP A/S
Grusbakken 8
DK-2820 Gentofte
Denmark

Phone (+45) 4362 6332
Fax (+45) 4362 6331

Mail info@antibodyshop.com
Web www.antibodyshop.com

WWW.ANTIBODYSHOP.COM